Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of DaVita HealthCare Partners Inc. (NYSE:DVA) by 0.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 508,512 shares of the company’s stock after buying an additional 685 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned about 0.25% of DaVita HealthCare Partners worth $39,318,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in DVA. Speece Thorson Capital Group Inc. boosted its stake in shares of DaVita HealthCare Partners by 1.4% in the second quarter. Speece Thorson Capital Group Inc. now owns 181,101 shares of the company’s stock valued at $14,003,000 after buying an additional 2,560 shares during the last quarter. Geode Capital Management LLC raised its stake in DaVita HealthCare Partners by 1.0% in the first quarter. Geode Capital Management LLC now owns 1,417,807 shares of the company’s stock valued at $103,840,000 after buying an additional 13,776 shares during the period. Whittier Trust Co. raised its stake in DaVita HealthCare Partners by 3.5% in the second quarter. Whittier Trust Co. now owns 46,414 shares of the company’s stock valued at $3,588,000 after buying an additional 1,548 shares during the period. ING Groep NV bought a new stake in DaVita HealthCare Partners during the first quarter valued at $278,000. Finally, Arizona State Retirement System raised its stake in DaVita HealthCare Partners by 0.6% in the first quarter. Arizona State Retirement System now owns 99,086 shares of the company’s stock valued at $7,271,000 after buying an additional 600 shares during the period. 83.54% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for DaVita HealthCare Partners (NYSE:DVA)

Shares of DaVita HealthCare Partners Inc. (NYSE:DVA) traded up 0.43% during mid-day trading on Wednesday, reaching $62.78. The company’s stock had a trading volume of 1,614,675 shares. The firm has a 50 day moving average price of $64.35 and a 200 day moving average price of $72.14. The firm has a market cap of $12.99 billion, a price-to-earnings ratio of 36.52 and a beta of 0.96. DaVita HealthCare Partners Inc. has a 52-week low of $61.36 and a 52-week high of $78.94.

DaVita HealthCare Partners (NYSE:DVA) last released its quarterly earnings results on Monday, August 8th. The company reported $1.01 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.98 by $0.03. The business earned $3.72 billion during the quarter, compared to analysts’ expectations of $3.67 billion. DaVita HealthCare Partners had a return on equity of 16.48% and a net margin of 2.51%. The firm’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same period last year, the firm posted $0.95 EPS. On average, equities analysts predict that DaVita HealthCare Partners Inc. will post $3.76 EPS for the current fiscal year.

Several research firms recently weighed in on DVA. JPMorgan Chase & Co. boosted their target price on DaVita HealthCare Partners from $74.00 to $75.00 and gave the stock a “neutral” rating in a report on Tuesday, August 9th. Raymond James Financial Inc. upgraded DaVita HealthCare Partners from a “market perform” rating to an “outperform” rating and set a $75.00 target price for the company in a report on Tuesday, September 20th. Zacks Investment Research lowered DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a report on Wednesday, July 27th. SunTrust Banks Inc. set a $66.00 target price on DaVita HealthCare Partners and gave the stock a “hold” rating in a report on Thursday, October 13th. Finally, Citigroup Inc. began coverage on DaVita HealthCare Partners in a report on Tuesday, September 6th. They issued a “neutral” rating and a $71.00 target price for the company. One research analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $75.50.

In related news, COO Michael David Staffieri sold 20,262 shares of DaVita HealthCare Partners stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $73.09, for a total transaction of $1,480,949.58. Following the completion of the sale, the chief operating officer now directly owns 52,279 shares of the company’s stock, valued at approximately $3,821,072.11. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 2.10% of the company’s stock.

DaVita HealthCare Partners Company Profile

DaVita HealthCare Partners Inc is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. Its segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives. Its Kidney Care division is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD).

5 Day Chart for NYSE:DVA

Receive News & Stock Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related stocks with our FREE daily email newsletter.